Petrovax Pharm completes the largest pneumococcal vaccine supply on schedule

Petrovax Pharm has fully fulfilled its government contract for the supply of a pneumococcal vaccine under the National Preventive Immunization Schedule. Over a two-year period, more than 8.7 million doses of the vaccine were delivered to regions across the Russian Federation for the immunization of infants in their first year of life, ensuring protection of all newborns against one of the most dangerous bacterial infections.

Pneumococcal infection is one of the leading causes of bacterial pneumonia in children. It can also result in meningitis, sepsis, and other severe complications. According to experts, the inclusion of pneumococcal vaccination in the Russian NIS has reduced mortality from community-acquired pneumonia among children under one year of age by 35%^[1].

Under the two-year government contract, the tender for which took place in October 2024, Petrovax Pharm has supplied more than 8.7 million doses of the vaccine for the immunization of infants. In addition, over the past two years, approximately 3 million doses have been procured by regional authorities for the vaccination of at-risk adults and the elderly.

Vaccination against pneumococcal infection is carried out within the framework of the National Preventive Immunization Schedule, where it has been included since 2014, as well as under the immunization schedule for epidemiological indications^[2]. It is recommended for children aged from two months to five years, as well as for at-risk adults, including conscripts, individuals over 60 years of age with chronic lung diseases, and residents of long-term care facilities.

Approximately 5.8 million doses of pneumococcal vaccine are procured annually in Russia, ensuring full coverage of pediatric immunization needs, as well as vaccination of at-risk adults and elderly populations. The use of the modern vaccine Prevenar^® 13, manufactured in Russia, has significantly reduced mortality among children^[1] and decreased the incidence of severe pneumonia in adult patients with chronic conditions^{[3], [4]}.

The development of immunization programs and the use of modern domestically produced vaccines remain key components of preventive medicine and major factors in reducing mortality from infectious diseases.